This is a randomized prospective open-label cohort study in patients with COVID-19 to evaluate the impact of Oscillation and Lung Expansion (OLE) therapy using The MetaNeb® System on the hospital length of stay in patients hospitalized and receiving heated high-flow oxygen therapy for COVID-19 infection. The active treatment group will consist of patients who are treated OLE therapy while on heated high-flow oxygen therapy .
Results from subjects in the active treatment group will be compared to results from patients treated with standard care with no OLE therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patient (\> 18 years of age)
Tested positive or person under investigation (PUI) for COVID-19 infection
Currently require heated high-flow oxygen therapy to maintain SaO2 \> 90 %
Signed informed consent (phone consent)
Heated high-flow oxygen initiated within the past 72 hours
You may not be if
Serious medical condition that, in the investigator's judgment, precludes the patient's safe participation in the study
Pressure related risk for pneumothorax
Patient inability or unwillingness to tolerate OLE therapy
Staff unavailable or unable to deliver therapy
Current requirement for mechanical ventilation or expected requirement for mechanical ventilation within the next 12 hours